Evaluation of the Significance of Cell Free DNA Epigenetic Markers as Predicative Factors for Nonalcoholic Fatty Liver Disease (NAFLD)
-
- STATUS
- Not Recruiting
Summary
The specific aims of this study are to provide a source of whole blood samples from subjects diagnosed with NASH (nonalcoholic steatohepatitis) to:
Test the hypothesis that absence of NAFL (nonalcoholic fatty liver) can be distinguished from early stage NAFLD (nonalcoholic fatty liver disease) and NASH w/o and NASH w/ fibrosis groups using cfDNA Cell free DNA) and/or epigenetic markers such as elevated liver fraction, hepatic stellate cell activation, novel plasma methylation patterns or a combination thereof.
Test the hypothesis that early stage NAFLD can be distinguished from NASH w/o and NASH w/ fibrosis groups using cfDNA and/or epigenetic markers such as elevated liver fraction, hepatic stellate cell activation, novel plasma methylation patterns or a combination thereof.
Test the hypothesis that NASH w/o fibrosis can be distinguished from NASH w/ fibrosis group using cfDNA and/or epigenetic markers such as elevated liver fraction, hepatic stellate cell activation, novel plasma methylation patterns or a combination thereof.
Description
The specific aims of this study are to provide a source of whole blood samples from subjects diagnosed with NASH (nonalcoholic steatohepatitis) to:
Test the hypothesis that absence of NAFL (nonalcoholic fatty liver) can be distinguished from early stage NAFLD (nonalcoholic fatty liver disease) and NASH w/o and NASH w/ fibrosis groups using cfDNA Cell free DNA) and/or epigenetic markers such as elevated liver fraction, hepatic stellate cell activation, novel plasma methylation patterns or a combination thereof.
Test the hypothesis that early stage NAFLD can be distinguished from NASH w/o and NASH w/ fibrosis groups using cfDNA and/or epigenetic markers such as elevated liver fraction, hepatic stellate cell activation, novel plasma methylation patterns or a combination thereof.
Test the hypothesis that NASH w/o fibrosis can be distinguished from NASH w/ fibrosis group using cfDNA and/or epigenetic markers such as elevated liver fraction, hepatic stellate cell activation, novel plasma methylation patterns or a combination thereof.
Details
| Condition | Nonalcoholic Fatty Liver Disease |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX8431 |
| Last Modified on | 19 February 2024 |
Similar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.